LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Search

Fulgent Genetics Inc

Закрыт

СекторЗдравоохранение

22.43 2.23

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

21.74

Макс.

22.54

Ключевые показатели

By Trading Economics

Доход

-7.4M

-19M

Продажи

8.3M

82M

Рентабельность продаж

-23.539

Сотрудники

1,313

EBITDA

-3.5M

-15M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+14.98% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

7 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

124M

673M

Предыдущая цена открытия

20.2

Предыдущая цена закрытия

22.43

Техническая оценка

By Trading Central

Уверенность

Bearish Evidence

Fulgent Genetics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

18 сент. 2025 г., 23:56 UTC

Популярные акции

Stocks to Watch: FedEx, 22nd Century, Scholastic

18 сент. 2025 г., 22:01 UTC

Главные движущие силы рынка

22nd Century Group Shares Gain on Debt Repayment, New Capital

18 сент. 2025 г., 20:51 UTC

Приобретения, слияния, поглощения

UPS Terminates Plan to Buy Estafeta

18 сент. 2025 г., 20:31 UTC

Отчет

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping -- Update

18 сент. 2025 г., 20:26 UTC

Отчет

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping

18 сент. 2025 г., 23:43 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

18 сент. 2025 г., 23:43 UTC

Обсуждения рынка

Nikkei May Rise on U.S. Stock Gains, Weaker Yen -- Market Talk

18 сент. 2025 г., 23:43 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

18 сент. 2025 г., 23:40 UTC

Обсуждения рынка

Gold Edges Lower Amid Cautious Mood -- Market Talk

18 сент. 2025 г., 23:31 UTC

Обсуждения рынка

FedEx Says U.S. Demand Is Resilient -- Market Talk

18 сент. 2025 г., 22:03 UTC

Отчет

FedEx Expects Trade Environment to Create $1B Headwind in 2026, CFO Says

18 сент. 2025 г., 22:01 UTC

Отчет

FedEx CFO: Asia-to-U.S. Declines Drove $150M International Export Headwind

18 сент. 2025 г., 21:56 UTC

Отчет

Lennar Missed Revenue Estimates. The Stock Is Down. -- Barrons.com

18 сент. 2025 г., 21:54 UTC

Отчет

FedEx Focused on Demand From Southeast Asia, Europe Amid China Shipping Slowdown, Customer Chief Says

18 сент. 2025 г., 21:48 UTC

Отчет

FedEx International Export Volumes Declined, Especially on China-to-U.S. Lane, Exec Says

18 сент. 2025 г., 21:47 UTC

Отчет

FedEx Had 5% Increase in U.S. Domestic Average Daily Package Volume in 1Q, Customer Chief Says

18 сент. 2025 г., 21:17 UTC

Отчет

FedEx Profit, Sales Rise on Improvement in U.S. Shipping -- 2nd Update

18 сент. 2025 г., 21:07 UTC

Отчет

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 сент. 2025 г., 20:50 UTC

Обсуждения рынка

Auto & Transport Roundup: Market Talk

18 сент. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

18 сент. 2025 г., 20:50 UTC

Обсуждения рынка
Отчет

Financial Services Roundup: Market Talk

18 сент. 2025 г., 20:50 UTC

Обсуждения рынка

Energy & Utilities Roundup: Market Talk

18 сент. 2025 г., 20:22 UTC

Приобретения, слияния, поглощения

UPS Cites Inability of All Closing Conditions to Be Satisfied

18 сент. 2025 г., 20:22 UTC

Приобретения, слияния, поглощения

United Parcel Service Terminates Plan to Buy Estafeta

18 сент. 2025 г., 20:20 UTC

Приобретения, слияния, поглощения

Here's How Much the U.S. Has Made on Its Intel Stock Purchase -- Barrons.com

18 сент. 2025 г., 20:18 UTC

Отчет

Nucor Stock Falls After Earnings. Why Its Guidance Was Far Off Rival Steel Dynamics. -- Barrons.com

18 сент. 2025 г., 20:18 UTC

Отчет

Bullish Crushes Earnings. The Crypto Stock Pops. -- Barrons.com

18 сент. 2025 г., 20:15 UTC

Обсуждения рынка

Global Commodities Roundup: Market Talk

18 сент. 2025 г., 20:07 UTC

Отчет

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 сент. 2025 г., 20:03 UTC

Отчет

FedEx 1Q FedEx Freight Segment Revenue $2.26B >FDX

Сравнение c конкурентами

Изменение цены

Fulgent Genetics Inc Прогноз

Целевая цена

By TipRanks

14.98% рост

Прогноз на 12 месяцев

Средняя 25.33 USD  14.98%

Максимум 30 USD

Минимум 21 USD

Основано на мнении 3 аналитиков Wall Street, спрогнозировавших целевые цены для Fulgent Genetics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

3 ratings

2

Покупка

1

Удержание

0

Продажа

Техническая оценка

By Trading Central

17.32 / 19.04Поддержка и Сопротивление

Краткосрочная

Bearish Evidence

Среднесрочная

Strong Bullish Evidence

Долгосрочная

Neutral Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
help-icon Live chat